Pharma and BioTech Daily

5:21

Novartis's $7.8B mRNA Deal with Abogen | Pharma and...

Pharma and BioTech Daily ·

2026/10/05

Good morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the rapidly evolving landscape of drug development, where groundbreaking scientific advances and strategic corporate maneuvers are reshaping patient care and industry standards.The integration of artificial intelligence in drug discovery is gaining momentum, with companies like Xaira Therapeutics leading the way. By leveraging AI to enhanc...

en-us

4:28

Sanofi's $1B Deal with Regeneron: Immunology...

Pharma and BioTech Daily ·

2026/10/02

Good morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. The landscape is constantly evolving, with innovative partnerships, groundbreaking clinical trial results, and regulatory shifts shaping the future of healthcare. Today, we delve into these key areas, highlighting significant industry movements and their potential impacts on patient care.Sanofi's renewed collaboration with Regeneron marks a pivotal strategic m...

en-us

5:52

Eli Lilly's Retatrutide: 25% Weight Loss in Phase 3...

Pharma and BioTech Daily ·

2026/10/01

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the latest breakthroughs and trends shaping the landscape of medicine and treatment.In the realm of weight management and metabolic disorders, significant advancements are underway. Roche and Zealand Pharma have moved Petrelintide, an amylin analog, into a Phase 3 clinical trial after a promising Phase 2 showing a nearly 10% weight loss in...

en-us

5:13

AstraZeneca's $2B Oncology Investment | Pharma and...

Pharma and BioTech Daily ·

2026/09/30

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.Today, we delve into a series of transformative developments across the pharmaceutical and biotech sectors, highlighting strategic investments, innovative therapies, and regulatory milestones. AstraZeneca's recent $2 billion investment in Summit Therapeutics is a testament to the industry's focus on cutting-edge oncology solutions. This substantial funding aim...

en-us

5:06

AbbVie Juvmo FDA Approved: Parkinson's Breakthrough |...

Pharma and BioTech Daily ·

2026/09/29

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Recent updates in these sectors have highlighted significant scientific advancements, regulatory milestones, and promising clinical trial results that could impact patient care and drug development.One of the standout developments is the FDA's approval of AbbVie's Juvmo, marking a new chapter in Parkinson's disease treatment. As the first selective D1/D5 recep...

en-us

4:56

Merck's FDA Win: Welireg & Lenvima Breakthrough |...

Pharma and BioTech Daily ·

2026/09/28

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The landscape of these industries is currently experiencing a wave of transformative changes, from strategic corporate relocations and groundbreaking partnerships to pivotal regulatory approvals and promising clinical trial outcomes.Let's begin with a significant corporate strategy shift. Lundbeck has made the decision to relocate its U.S. headquarters to Bost...

en-us

4:43

Eli Lilly's $2B Onswik FDA Approval Revolutionizes...

Pharma and BioTech Daily ·

2026/09/25

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of recent breakthroughs and strategic moves that are shaping the future of drug development and patient care.Eli Lilly has achieved a significant milestone with the FDA's approval of Onswik, a once-weekly insulin therapy for type 2 diabetes. This innovative treatment is set to revolutionize diabetes management by offering a mo...

en-us

5:06

AstraZeneca's Trixeo EU Approval & Boehringer's $250M...

Pharma and BioTech Daily ·

2026/09/24

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the dynamic landscape of scientific advances and strategic collaborations shaping patient care and drug development globally.AstraZeneca recently achieved a significant milestone with the European Union's approval of Trixeo, a combination therapy for asthma. This approval follows a successful Phase 3 trial, highlighting its effectiveness i...

en-us

5:18

Boehringer Ingelheim's $1B AI Deal & FDA Trials...

Pharma and BioTech Daily ·

2026/09/23

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The industry is pulsating with advancements, strategic collaborations, regulatory approvals, and promising clinical trial results that are reshaping the landscape of healthcare and drug development.A notable collaboration making waves is between Boehringer Ingelheim and Envisagenics, a partnership valued at $1 billion. This multi-year agreement harnesses artif...

en-us

4:45

Telix Buys ITM for $2.35B | Pharma and Biotech Daily

Pharma and BioTech Daily ·

2026/09/22

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a period of profound transformation within the industry, marked by scientific advancements, strategic acquisitions, and a shifting regulatory landscape that promises to redefine the future of healthcare.Telix Pharmaceuticals has made headlines with its acquisition of ITM Isotope Technologies Munich SE, valued at up to $2.35 billion. This m...

en-us

4:40

Ultragenyx’s $4M Fayuvi FDA Approval Breakthrough |...

Pharma and BioTech Daily ·

2026/09/21

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of groundbreaking advancements and strategic shifts shaping the future of this dynamic industry.The FDA has recently approved Ultragenyx's gene therapy, Fayuvi, for a rare neurodegenerative disorder, marking a significant milestone in the realm of precision medicine. Gene therapies like Fayuvi offer a beacon of hope for conditions...

en-us

4:41

Bayer's Kerendia Secures 3rd FDA Approval | Pharma...

Pharma and BioTech Daily ·

2026/09/18

Good morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of pivotal advancements and strategic maneuvers shaping the landscape of drug development and patient care.Bayer's Kerendia, known generically as finerenone, has achieved its third FDA approval, this time targeting chronic kidney disease linked with type 1 diabetes. This small molecule mineralocorticoid receptor antagonist pla...

en-us

4:59

Novartis Acquires Sironax Platform for $125M | Pharma...

Pharma and BioTech Daily ·

2026/09/17

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of dynamic and significant advancements across the industry, from strategic acquisitions to regulatory shifts and scientific innovations.In a bold move, Novartis has acquired Sironax's blood-brain barrier delivery platform for $125 million. This acquisition marks a strategic enhancement in Novartis's ability to deliver therapi...

en-us

4:53

GSK Acquires Chimagen's Tech for $750M | Pharma and...

Pharma and BioTech Daily ·

2026/09/16

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant strides and strategic maneuvers reshaping the landscape of healthcare and drug development.Kicking things off, GlaxoSmithKline (GSK) has made headlines with its acquisition of Chimagen Biosciences' trispecific T cell engager technology, targeting multiple myeloma. This move, valued at up to $750 million, highlights ...

en-us

5:10

Scholar Rock's $20B Pharma Shakeup & More | Pharma...

Pharma and BioTech Daily ·

2026/09/15

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today’s episode delves into some of the latest breakthroughs, regulatory updates, and strategic maneuvers reshaping the landscape of drug development and patient care.Starting with remarkable advancements in drug approvals, Scholar Rock's Isembldy (apitegromab), a monoclonal antibody designed to inhibit myostatin, has secured FDA approval for treating spinal m...

en-us

5:55

Moderna's $1B mRNA Cancer Vaccine Boosts Personalized...

Pharma and BioTech Daily ·

2026/09/14

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.First, let's delve into the innovative work being done by Grove Biopharma. Founded in 2020 in Chicago, this company is at the forefront of developing polymer-peptide hybrids to target intracellular protein-protein interactions, areas traditionally deemed undruggable. These interactions are crucial regulatory components in numerous cellular processes and are imp...

en-us

4:55

FDA Expands Bayer's Hyrnuo Approval | Pharma and...

Pharma and BioTech Daily ·

2026/09/11

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the significant advancements and challenges that are shaping the future of drug development, regulatory landscapes, and industry innovations.Starting with a major milestone in personalized cancer therapy, the FDA has expanded Bayer's approval for Hyrnuo (zipalertinib) to include its use as a first-line treatment for HER2-mutant non-small c...

en-us

4:42

Sandoz Invests $2.5B in Biosimilars Network | Pharma...

Pharma and BioTech Daily ·

2026/09/10

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.Sandoz's recent move to invest $2.5 billion in creating a vertically integrated biosimilar manufacturing network is making waves across the industry. This significant investment underscores the growing importance of biosimilars as cost-effective alternatives to biologics. With plans to develop 100 biosimilars by 2040, Sandoz is strategically positioning itself ...

en-us

5:06

AstraZeneca's $116M FDA Win: New Breast Cancer Drug |...

Pharma and BioTech Daily ·

2026/09/09

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we unveil a series of transformative strides in drug approvals, clinical trials, and regulatory landscapes that are reshaping the future of patient care.AstraZeneca's camizestrant, now branded as Etcamah, has received FDA approval for treating ESR1-mutated hormone receptor-positive, HER2-negative advanced breast cancer. This approval is a testament to t...

en-us

4:38

FDA Approves Alzheimer's Drug: Major $ Breakthrough |...

Pharma and BioTech Daily ·

2026/09/08

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. In today's episode, we're diving into a series of breakthroughs and significant updates that are shaping the landscape of medicine and treatment. Let's start with a remarkable development in the realm of personalized medicine. Researchers have announced a breakthrough in gene-editing technology that holds promise for treating a range of genetic disorders. This ...

en-us

All Episodes

Similar Podcasts

Expres Ráno

Expres FM

Quick Start

CBN News

Bloomberg News Now

Bloomberg

Israel Today: Ongoing War Report

Noa Levi

The Decibel

The Globe and Mail